Gilead Sciences Inc

Type: Company
Name: Gilead Sciences Inc
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Gilead Sciences' Trademark Application for "HIV ANSWERS" Filed

By a News Reporter-Staff News Editor at AIDS Weekly -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a trademark application has been made for "HIV ANSWERS" by Gretchen R. Stroud , representing Gilead Sciences ... [Published 4 Traders - 4 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 2 reports

InterMune Drug May Offer Big Upside To Roche If Aimed At Liver

By Ransdell Pierson and Bill Berkrot (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the ... [Published Clusterstock - 5 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Gilead, Jazz Among 4 Top Big Cap Medicals To…

Jazz PharmaceuticalsBest-selling narcolepsy medication Xyrem made up two-thirds of Jazz's second-quarter sales. The company acquired Italian biotech Gentium earlier in the year.View Enlarged ImageJazz shares rose 1.7% to 163.56 on the stock market Tuesday, ... [Published Investor's Business Daily - 8 hours ago]
First reported 11 hours ago - Updated 10 hours ago - 2 reports

Gilead Sciences (GILD) Approaches New Upside Target of $110.54

Written on Wed, 08/27/2014 - 1:18pmBy David DiazShares of Gilead Sciences ( NASDAQ:GILD ) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next ... [Published Comtex SmarTrend - 10 hours ago]
First reported 13 hours ago - Updated 12 hours ago - 2 reports

Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock...

Isis Pharmaceuticals, Inc. ( ISIS ) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend ... [Published Nasdaq - 13 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

GILEAD SCIENCES : Continuation of the bullish trend

Gilead Sciences is trading in a bullish trend and several arguments are in favor of the continuation of this trend.From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus regularly revised upward sales and EPS estimates of the ... [Published 4 Traders - 12 hours ago]
First reported Aug 26 2014 - Updated 15 hours ago - 3 reports

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Want a window into the future of hepatitis C drug marketing? Keep an eye on Europe. Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead ... [Published FiercePharma - 15 hours ago]
First reported Aug 26 2014 - Updated 16 hours ago - 4 reports

Futures point to flat Wall St. open; S&P 500 near record

U.S. stock index futures pointed to very slight gains at the open on Tuesday, with investors finding few reasons to buy after a rally in the previous session that took the S&P 500 index above 2,000 for the first time.The benchmark S&P failed to hold that ... [Published 4 Traders - Aug 26 2014]
First reported Aug 26 2014 - Updated 22 hours ago - 2 reports

Should Gilead Sciences, inc. Fear This New Competitor Drug?

According to ViiV Healthcare -- GlaxoSmithKline (NYSE: GSKThat creates a significant hurdle for policy makers eager to lower HIV incidence rates and drugmakers eager to boost prescription volume for next-generation therapies.As a result, drugmakers are ... [Published Motley Fool - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 2 reports

Gilead: Earnings Forecast Justifies $140 Price Target

By Leonard Yaffe :I have been recommending Gilead (NASDAQ: GILD ) for the past 3 years, and for the past 2 years my price target has been $140. Below, I shall discuss the company's current earnings stream, largely driven by Hepatitis C , as well as a ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Gilead Sciences: Despite This Year's Triumphs, Watch Out For Weaknesses - An Algorithmic Perspective

By I Know First Research :Consult the Internet concerning Gilead Sciences ( GILD ), and you will presently find nothing but bulls. Barron's advises us not to worry about a pricing war, The Fool gives us three reasons Gilead stock could rise, Ticker Report ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 2 reports

TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape

TrovaGene, Inc. ( TROV ) was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, ... [Published Zacks.com - Aug 26 2014]

Quotes

"FIG. 2 shows a characteristic DSC trace for the succinate salt of Ethyl N--[(S)({[(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofur-"

More Content

All (1879) | News (1323) | Reports (0) | Blogs (508) | Audio/Video (0) | Fact Sheets (7) | Press Releases (32)
sort by: Date | Relevance
Gilead Sciences : "Salts of Hiv Inhibitor Compo... [Published 4 Traders - 2 hours ago]
GILEAD SCIENCES : "Apoptosis Signal-Regulating ... [Published 4 Traders - 2 hours ago]
Gilead Sciences' Trademark Application for "HIV... [Published 4 Traders - 4 hours ago]
Alkermes Begins a Study on ALKS7106 for Treatme... [Published Zacks.com - 5 hours ago]
Rescuing Compassionate Use From Social Media An... [Published Forbes.com - 5 hours ago]
InterMune Drug May Offer Big Upside To Roche If... [Published Clusterstock - 5 hours ago]
ANALYSIS-InterMune drug may offer big upside to... [Published CNBC - 5 hours ago]
Biogen's Eloctate Approved in Canada for Hemoph... [Published Zacks.com - 6 hours ago]
Alexion's Soliris Manufacturing Facility Fails ... [Published Zacks.com - 7 hours ago]
Biotech ETFs Hitting New Highs On Takeover News... [Published Benzinga.com - 8 hours ago]
Gilead, Jazz Among 4 Top Big Cap Medicals To… [Published Investor's Business Daily - 8 hours ago]
10 things to know about specialty drug spending [Published Beckers Hospital Review - 9 hours ago]
Healthy Earnings Growth Sustains Pricey Biotech... [Published Yahoo! Finance - 9 hours ago]
Gilead Sciences (GILD) Approaches New Upside Ta... [Published Comtex SmarTrend - 10 hours ago]
EU green light for B-MS hepatitis C drug [Published Pharma Times - 11 hours ago]
Highest EPS Growth in the Biotechnology Industr... [Published Individual.com - 11 hours ago]
Goldman Sachs' 50 Stocks That Matter Most to He... [Published TheStreet.com - 12 hours ago]
GILEAD SCIENCES : Continuation of the bullish t... [Published 4 Traders - 12 hours ago]
Goldman Sachs' 50 Stocks That Matter Most to He... [Published The Street Latest - 12 hours ago]
Is It Time to Buy AbbVie Stock? [Published Motley Fool Discussion Boards - 12 hours ago]
Shocking Prediction #9: 'Nightmare Pandemics' C... [Published StreetAuthority - 13 hours ago]
Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock... [Published Nasdaq - 13 hours ago]
Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock... [Published Zacks.com - 13 hours ago]
Here’s How The Rest Of The Year Will Hold Up Fo... [Published Bidness Etc - 14 hours ago]
S&P 2,000: Speed Bump Or Top? [Published Seeking Alpha - 14 hours ago]
3 Reasons Pfizer Inc.'s Stock Could Fall [Published Motley Fool Discussion Boards - 14 hours ago]
Roche, InterMune a Strategic Play in Midst of I... [Published The Street Latest - 14 hours ago]
Upcoming Conference Schedule, Scholarship, Appr... [Published Financial Services - 14 hours ago]
Amicus Therapeutics Hits 52-Week High on Migala... [Published Zacks.com - 14 hours ago]
Early Analysis: Israel, Ukraine in Focus [Published State Of The Markets.com - 14 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
InterMune Drug May Offer Big Upside To Roche If... [Published Clusterstock - 5 hours ago]
By Ransdell Pierson and Bill Berkrot (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the ...
Biotech Stocks: Time to Worry [Published BARRONS.com Stocks To Watch Today - Aug 26 2014]
Remember when the biotech world was falling apart? Neither do we. I mean, just look at these returns: Gilead Sciences (GILD) has gained 41% so far this year as investors appear to have put their Sovaldi worries behind them; InterMune (ITMN) has quintupled ...
Global Cytomegalovirus Retinitis Market 2014-20... [Published PR Newswire: Health - Aug 26 2014]
DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative ...
Gilead Sciences (GILD) Trading Near $109.12 Res... [Published MarketIntelligenceCenter.com - Aug 26 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithms on Gilead Sciences Inc (GILD) could yield about 6.33% (43.60% annualized, for comparison purposes only) in 53 days. Pair a long position in the stock with the Oct. '14 $110.00 ...
Futures Flat, Few Incentives To Buy; S&P 500 Of... [Published Clusterstock - Aug 26 2014]
<p><img class="float_right" src="http://static3.businessinsider.com/image/53fb1d415afbd390028b456c-450-300/futures-rise-on-hopes-for-ecb-action-merger-activity-2014-8.jpg" border="0" alt="Traders work on the floor of the New York Stock Exchange (NYSE) ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Upcoming Conference Schedule, Scholarship, Appr... [Published Financial Services - 14 hours ago]
Critical Alerts For Gilead Sciences, Disney, St... [Published Financial Services - Aug 21 2014]
Zacks Earnings Trends Highlights: Wal-Mart, Mac... [Published Financial Services - Aug 15 2014]
Zacks.com featured expert Kevin Matras highligh... [Published Financial Services - Aug 14 2014]
The Zacks Analyst Blog Highlights: Natural Gas ... [Published Financial Services - Aug 11 2014]
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.